dialogue – But What Do We Know?

Partially Examined Life

Xenon Forging Ahead in MDD Despite Mid-stage Flop November 27, 2023
While XEN1101 failed to hit the primary endpoint in a Phase II trial, the Canadian company is “actively exploring” further development of the program based on the totality of the data.
89bio Unveils Bullish Long-Term Data for NASH Candidate November 27, 2023
Pegozafermin showed statistically significant improvements in treating patients with nonalcoholic steatohepatitis, notching a win in the race to get the first treatment to market for the condition.
Regeneron and Sanofi Find Further Positive Results for Dupixent in COPD November 27, 2023
New data show the biologic significantly reduced exacerbations in chronic obstructive pulmonary disease, confirming positive results from an earlier trial.
GSK Builds Case for Blenrep’s Comeback with Promising Phase III Data November 27, 2023
A year after exiting the U.S. market, GSK is setting the stage for the antibody-drug conjugate's possible return in relapsed/refractory multiple myeloma.
Novo Warns EU of GLP-1 Drug Shortages, Expands Production at French Site November 27, 2023
Novo Nordisk is diverting manufacturing capacity away from its older GLP-1 drug Victoza in order to cater to sky-high Ozempic demand.